AI-Driven Discovery
Reshaping Biomedical Frontiers
AI-driven drug discovery using our proprietary AI-powered platform, MoleculeGEN.
How We're Harnessing AI to Transform Drug Discovery
De Novo Drug Design
De novo drug design is a computational approach that generates novel molecular structures from atomic building blocks without relying on previously known compounds as starting points. It aims to automate the creation of new chemical entities tailored to specific molecular characteristics.
Using our proprietary AI-driven computational tools, de novo design creates novel, drug-like small molecules for particular targets, including those related to diseases with high unmet needs.
Antibody Design
Drug design remains a challenging endeavor due to the complexity of the involved design space. Artificial Intelligence provides a unique shot at the problem due to its capability of enabling efficient horizon exploration.
We are applying our AI capabilities in screening and de novo generation of antibodies and small molecule drugs against challenging targets such as intrinsically disordered pathogenic proteoforms involved in Parkinson’s disease.
Multidisciplinary Expertise
Our team consists of an ideal mix of members having strong experience in both the fields of biophysics and AI. We strongly believe in the importance of a multidisciplinary team for tackling the problem.
Biophysics Meets Deep Learning
Deep Learning has revolutionized many fields but still remains in the nascent stages for drug design. Models like AlphaFold provide a strong foundation for the field but end-to-end solutions need to go far beyond. Hence, we develop novel architectures, built using biophysics principles at the core.
